Patents Assigned to University of Iowa Research Foundation
  • Tomatidine, analogs thereof, compositions comprising same, and uses for same
    Patent number: 10022386
    Abstract: In one aspect, the invention relates to methods for promoting muscle hypertrophy or decreasing adiposity by providing to an animal in need thereof an effective amount of a compound. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 17, 2018
    Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Christopher M. Adams, Michael C. Dyle, Michael Welsh
  • MUSCLIN PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20180194824
    Abstract: In certain embodiments, the present invention provides a musclin peptide and methods of increasing muscle growth, performance, resistance to injury and/or preventing or reducing muscle atrophy and improving overall skeletal muscle, metabolic and cardiac health in an animal in need thereof by administering a musclin peptide.
    Type: Application
    Filed: December 14, 2017
    Publication date: July 12, 2018
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Leonid Zingman, Denice Hodgson-Zingman
  • Transgenic pig models of cystic fibrosis
    Patent number: 10004212
    Abstract: This invention relates to transgenic pig models of cystic fibrosis, cells that can be used to make such animals, and methods of making and using these pigs and cells.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: June 26, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Michael J. Welsh, David Stoltz
  • Alternative export pathways for vector expressed RNA interference
    Patent number: 10006028
    Abstract: The present invention is directed to nucleic acid molecules containing a loop sequence designed to circumvent exportin-5 mediated export, and methods using these novel molecules.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: June 26, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Scott Harper, Beverly L. Davidson
  • METHODS OF DELIVERY OF TRANSGENES FOR TREATING BRAIN DISEASES
    Publication number: 20180169269
    Abstract: The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's deep cerebella nuclei a recombinant adeno-associated virus (rAAV) particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a therapeutic agent inserted between a pair of AAV inverted terminal repeats in a manner effective to infect the CNS cell of the non-rodent mammal such that the CNS cell expresses the therapeutic agent in the non-rodent mammal.
    Type: Application
    Filed: May 31, 2016
    Publication date: June 21, 2018
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Beverly L. Davidson, Megan S. Keiser
  • Methods of improving RNAi in well-differentiated airway epithelia
    Patent number: 9987299
    Abstract: The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a facilitating agent followed by contacting the cell with a therapeutic RNAi agent, wherein the facilitating agent comprises a Platelet-activating factor receptor (PAFR) ligand.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: June 5, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Paul B. McCray, Jr., Beverly L. Davidson, Michael A. Apicella, Sateesh Krishnamurthy
  • USE OF NAD PRECURSORS FOR BREAST ENHANCEMENT
    Publication number: 20180147225
    Abstract: Certain embodiments of the invention provide a method for breast enhancement in a female mammal (e.g., a human) in need thereof, comprising administering an effective amount of a nicotinamide adenine dinucleotide (NAD) precursor to the mammal.
    Type: Application
    Filed: November 29, 2017
    Publication date: May 31, 2018
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Charles M. Brenner, Po Hien Ear, Ankita Chadda, Amy Sindler, Marie E. Migaud
  • METHODS FOR TREATING TUMORS IN SITU INCLUDING INTRATUMOR INJECTION OF CYTOTOXIC PARTICLES AND IMMUNE CHECKPOINT BLOCKADE THERAPY
    Publication number: 20180147224
    Abstract: Disclosed are compositions, kits, and methods for treating cancer in a subject in need thereof. The compositions, kits, and methods may be used to treat a tumor in a subject in situ. The compositions, kits, and methods comprise or utilize cytotoxic particles, immune checkpoint inhibitors, and/or T-cell stimulatory agents.
    Type: Application
    Filed: May 16, 2016
    Publication date: May 31, 2018
    Applicant: University of Iowa Research Foundation
    Inventors: Aliasger K. Salem, Amani Makkouk, Vijaya B. Joshi, George Weiner
  • Image guided therapy for cancer
    Patent number: 9980951
    Abstract: The invention provides a method to treat cancer in an animal comprising administering a tetra-arylethylene cation to the animal.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 29, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Michael K. Schultz, Jessica Reedy, Christopher Pigge, Moustafa Tarek Ahmed Ibrahim Gabr, Mahboubeh Varmazyad, Prabhat C. Goswami
  • METHODS AND COMPOSITIONS FOR TREATING GENETIC EYE DISEASES
    Publication number: 20180142259
    Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targetting peptides that deliver agents, to the eye. The present inventors have discovered peptides that function to target agents, such as viral vectors, to ocular cells. The present disclosure describes a method to utilize these novel peptides to direct, for example, viral capsids to the cell type of interest. In this instance, ocular cells (such as retinal cells) are targeted by the identified peptides. Vectors harboring capsid proteins modified to include such peptides can be used to provide therapeutic agents to the eye.
    Type: Application
    Filed: February 22, 2016
    Publication date: May 24, 2018
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, FONDAZIONE TELETHON
    Inventors: Beverly L DAVIDSON, Yong Hong CHEN, Alberto AURICCHIO
  • NUCLEIC ACID APTAMERS TO TREAT HISTONE-INDUCED DISEASE STATES
    Publication number: 20180134746
    Abstract: The present invention relates to optimized aptamers and methods of using these aptamers.
    Type: Application
    Filed: December 22, 2015
    Publication date: May 17, 2018
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Paloma H. Giangrande, Francis Miller, Kevin Urak
  • CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
    Publication number: 20180127783
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Application
    Filed: November 29, 2017
    Publication date: May 10, 2018
    Applicants: EDITAS MEDICINE, INC., THE BROAD INSTITUTE INC., THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, MASSACHUSETTS INSTITUITE OF TECHNOLOGY
    Inventors: Feng ZHANG, Deborah PALESTRANT, Beverly DAVIDSON, Jordi MATA-FINK, Edgardo RODRIGUEZ, Alexis BORISY
  • METHODS FOR INHIBITING MUSCLE ATROPHY
    Publication number: 20180118657
    Abstract: In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 6, 2017
    Publication date: May 3, 2018
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Christopher M. ADAMS, Steven D. KUNKEL, Manish SUNEJA, Michael WELSH
  • Method for causing stochastic depolarization in the spinal cord to inhibit transmission of synchronous action potentials
    Patent number: 9950165
    Abstract: This invention provides a new technology for management of back pain by stimulating the spinal cord in a manner that renders it refractory to transmission of deleterious or undesirable sensory input. The electrical stimulus comprises high frequency pulses in a regular or complex pattern or that are stochastically produced under microprocessor control. The stimulus is applied directly to the surface of the spinal cord from within the spinal canal, which provides important benefits over previous technology. The stimulus alleviates symptoms and signs of back pain, while minimizing the risk of side effects such as paresthesia, and potentially minimizing the effects on motor neuron transmission and proprioception.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: April 24, 2018
    Assignee: University of Iowa Research Foundation
    Inventor: Matthew A. Howard
  • Peptide inhibitor of Nox1 NADPH oxidase
    Patent number: 9951102
    Abstract: An isolated peptide or fusion having the peptide useful to interfere with the phosphorylation of Nox1, block or inhibit binding of NoxA1 activation domain (AD) to Nox1, and/or prevent or inhibit assembly of the p47phox/NoxA1 complex with Nox1, or a vector encoding the peptide or fusion thereof, and methods of using the peptide, fusion or vector are provided.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: April 24, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Francis J. Miller, Jr., Jennifer Streeter
  • Inhibitors of phosphodiesterase type 5A for reducing skeletal muscle fatigue, edema, and damage in a patient having muscle fatigue due to increased age or exercise
    Patent number: 9943518
    Abstract: Disclosed are pharmaceutical compositions and methods for treating or preventing muscle diseases or the symptoms thereof. The compositions typically include and the methods typically utilize phosphodiesterase type 5A inhibitors.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: April 17, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Kevin P. Campbell, Yvonne M. Kobayashi, Robert W. Crawford
  • Therapeutic compounds
    Patent number: 9937177
    Abstract: The invention provides a compound of formula I: wherein X, Y, Z have any of the values defined in the specification or a salt thereof. The compound is useful as anti-cancer agents. The invention also provides processes and intermediates disclosed herein that are useful for preparing a compound of formula I or a salt thereof.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: April 10, 2018
    Assignee: University of Iowa Research Foundation
    Inventor: Leonard R. MacGillivray
  • Automated determination of arteriovenous ratio in images of blood vessels
    Patent number: 9924867
    Abstract: The methods and systems provided can automatically determine an Arteriolar-to-Venular diameter Ratio, AVR, in blood vessels, such as retinal blood vessels and other blood vessels in vertebrates. The AVR is an important predictor of increases in the risk for stroke, cerebral atrophy, cognitive decline, and myocardial infarct.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: March 27, 2018
    Assignees: University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Michael D. Abramoff, Melndert Niemeijer, Xiayu Xu, Milan Sonka, Joseph M. Reinhardt
  • VACCINE, THERAPEUTIC COMPOSITION AND METHODS FOR TREATING OR INHIBITING CANCER
    Publication number: 20180055920
    Abstract: The present invention provides a method of preparing an anti-cancer composition comprising activated immune cells and a pharmaceutically acceptable excipient. The present invention further provides a method of contacting immune cells obtained from an animal with an optimal combination of activating agents and with an immunogenic material to form the activated immune cells.
    Type: Application
    Filed: March 11, 2016
    Publication date: March 1, 2018
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventor: Gail Bishop
  • Neuroprotective compounds and use thereof
    Patent number: 9902713
    Abstract: Provided herein are compositions and methods for reducing one or both of axonal degeneration and neuronal cell death associated with a disease or traumatic brain injury. An aminopropyl carbazole agent with potent neuroprotective properties is described. Specifically, (?)-(S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine, is proposed as a new pharmacological agent for protecting patients against axonal degeneration and chronic consequences of TBI.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: February 27, 2018
    Assignees: Board of Regents of the University of Texas System, University of Iowa Research Foundation
    Inventors: Steven L. McKnight, Joseph M. Ready, Andrew A. Pieper